Pyrukynd is a medicine used to treat adults with pyruvate kinase deficiency (PKD), an inherited disease that causes red blood cells to break down faster than normal. PKD is rare, and Pyrukynd was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 22 April 2020. Further information on the orphan designation can be found here: [https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2270](/en/medicines/human/orphan-designations/eu-3-20-2270). Pyrukynd contains the active substance mitapivat.
Therapeutic Indication
### Therapeutic indication Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4).
Therapeutic Area (MeSH)
ATC Code
B06AX04
ATC Item
mitapivat
Pharmacotherapeutic Group
Other hematological agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| mitapivat sulfate | N/A | 吡那帕利 |
EMA Name
Pyrukynd
Medicine Name
Pyrukynd
Aliases
N/A
